Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer

F. Morgillo, F. De Vita, G. Antoniol, M. Orditura, P.P. Auriemma, M.R. Diadema, E. Lieto, B. Savastano, L. Festino, M.M. Laterza, A. Fabozzi, J. Ventriglia, A. Petrillo, F. Ciardiello, A. Barbarisi, F. Iovino


Increased insulin-like growth factor (igf) signalling has been observed in breast cancer, including endocrine-responsive cancers, and has been linked to disease progression and recurrence. In particular, igf-1 has the ability to induce and promote lymphangiogenesis through the induction of vascular endothelial growth factor C (vegfc). In the present study, we analyzed serum and tumour samples from 60 patients with endocrine-positive breast cancer to determine the expression and the possible relationship of circulating igf-1, igf binding protein 3 (igfbp3), and vegfc with the presence of lymphatic metastasis and other immunohistochemical parameters. The analysis revealed a clear and significant correlation between high basal levels of igf-1, igfbp3, and vegfc and lymph node metastasis in endocrine-responsive breast cancer. In addition, expression of those molecules was significantly higher in breast cancer patients than in healthy control subjects. Those findings may enable more accurate prediction of prognosis in patients with breast cancer.


Breast cancer; igf-1; vegfc

Full Text:



Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)